Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis
- 371 Downloads
Myasthenia gravis (MG) is an autoimmune disease caused by sensitization of the immune system to self-antigens. We have previously shown that targeting MG-susceptible alleles can significantly inhibit proliferation of disease-specific T cells. In this work, we humanized a murine monoclonal antibody (mAb) LG11, capable of blocking MG-associated DQ beta 1 (DQB1) allele and reformatted it into single-chain fragment variable (scFv). A fully functional humanized scFv was obtained by optimizing variable domain orientations and linker lengths, along with the optimization of expression conditions and codons to suit Escherichia coli expression machinery. Characterization of humanized scFv (FL8) revealed that the reformatted scFv, despite recognizing the same epitope as the parent murine LG11 mAb, exhibited superior binding affinity (0.97 nM) compared to the LG11 mAb, towards the immunizing antigen (DQB1*0601/70-90) and was able to block the proliferation of T cells cultured from PBLs of MG-patients typed DQB1*0601. The scFv was also capable of binding a variant MG-associated allele (DQB1*0502/70-90) with moderate affinity (18.7 nM), a feature that was absent in the LG11. To our knowledge, this is the first report of humanizing a MG-associated human leukocyte antigen (HLA) scFv for preclinical studies.
KeywordsMyasthenia gravis Antibody engineering Antibody humanization scFv Biacore Expression optimization
The authors wish to acknowledge Prof. Carlos F. Barbas III (The Scripps Research Institute, La Jolla, CA) for providing pComb3XSS vector; Dr. Minako Oshima for providing anti-DQB1*0601 mAb, synthetic peptides, and reagents for T cell assay; and Dr. Philip Deitiker for technical help with beta counter. Additionally, the authors would like to thank Dr. Timothy Palzkill and Dr. Zhizeng Sun for allowing us to use their Biacore instrument and providing useful suggestions during analysis. The authors appreciate the assistance of Dr. Sushrut Arora with the proof-reading and scientific editing.
Compliance with ethical standards
The authors accept the rules of good scientific practice and agree with the COPE guidelines followed by the Applied Microbiology and Biotechnology Journal.
Conflict of interest
The authors declare that they have no conflict of interest.
Procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Baylor College of Medicine. This article does not contain any studies with animals performed by any of the authors.
Blood samples were obtained from patients with the clinical diagnosis of generalized myasthenia. A written informed consent was obtained from the patients, which was approved by the Institutional Review Board of Baylor College of Medicine.
- Ayyar BV, Aoki KR, Atassi MZ (2015a) The C-terminal heavy-chain domain of botulinum neurotoxin A is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions. Infect Immun 83:1465–1476CrossRefPubMedPubMedCentralGoogle Scholar
- Conti-Fine BM, Diethelm-Okita B, Ostlie N, Wang W, Milani M (2009) Immunopathogenesis of myasthenia gravis. In: Kaminski H J (ed) Myasthenia gravis and related disorders. Humana Press, Totowa, pp 43–70Google Scholar
- Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, Lichtlen P, Urech DM (2009) Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti–TNF-α single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 50:771–778CrossRefPubMedGoogle Scholar
- Kabat E, Wu TT, Perry HM, Gottesman KS, Foeller C (1991) Sequence of proteins of immunological interest. Publication No 91-3242. US Public Health Services, NIH, BethesdaGoogle Scholar
- Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58:964–975CrossRefPubMedGoogle Scholar
- Kovalenko OV, Olland A, Piché-Nicholas N, Godbole A, King D, Svenson K, Calabro V, Müller MR, Barelle CJ, Somers W, Gill DS, Mosyak L, Tchistiakova L (2013) Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis. J Biol Chem 288(24):17408–17419CrossRefPubMedPubMedCentralGoogle Scholar
- Leite MI, Jones M, Ströbel P, Marx A, Gold R, Niks E, Verschuuren JJGM, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A, Willcox N (2007) Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 171:893–905CrossRefPubMedPubMedCentralGoogle Scholar
- Maniaol AH, Elsais A, Lorentzen ÅR, Owe JF, Viken MK, Sæther H, Flåm ST, Bråthen G, Kampman MT, Midgard R, Christensen M, Rognerud A, Kerty E, Gilhus NE, Tallaksen CME, Lie BA, Harbo HF (2012) Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 7:e36603CrossRefPubMedPubMedCentralGoogle Scholar
- Oshima M, Yokoi T, Deitiker P, Atassi MZ (1998) T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products. Autoimmunity 27(2):79–90CrossRefPubMedGoogle Scholar
- Oshima M, Deitiker PR, Mosier DR, Smith RG, Atassi MZ (2005a) Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor α-chain peptides: analysis in relation to age, thymic abnormality, and ethnicity. Hum Immunol 66:32–42CrossRefPubMedGoogle Scholar
- Saruhan-Direskeneli G, Hughes T, Yilmaz V, Durmus H, Adler A, Alahgholi-Hajibehzad M, Aysal F, Yentür SP, Akalin MA, Dogan O, Marx A, Gülsen-Parman Y, Oflazer P, Deymeer F, Sawalha AH (2016) Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clin Immunol 166–167:81–88CrossRefPubMedGoogle Scholar
- Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR, Barohn RJ, Dimachkie MM, Ciafaloni E, Broering TJ, Vigneault F, Nowak RJ, Kleinstein SH, O’Connor KC (2017) Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing. J Immunol 198:1460–1473CrossRefPubMedGoogle Scholar
- Vandiedonck C, Beaurain G, Giraud M, Hue-Beauvais C, Eymard B, Tranchant C, Gajdos P, Dausset J, Garchon H-J (2004) Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci U S A 101:15464–15469CrossRefPubMedPubMedCentralGoogle Scholar
- Vrolix K, Fraussen J, Losen M, Stevens J, Lazaridis K, Molenaar PC, Somers V, Bracho MA, Le Panse R, Stinissen P, Berrih-Aknin S, Maessen JG, Van Garsse L, Buurman WA, Tzartos SJ, De Baets MH, Martinez-Martinez P (2014) Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun 52:101–112CrossRefPubMedGoogle Scholar
- Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D (2000) Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J Immunol Methods 233:167–177CrossRefPubMedGoogle Scholar
- Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki AI, Newsom-Davis J, Cutter GR (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:511–522CrossRefPubMedPubMedCentralGoogle Scholar
- Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VES, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen S-L, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P (2007) Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39:329–337CrossRefPubMedPubMedCentralGoogle Scholar